美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Tevogen Bio Holdings Inc.

0.0326

+0.00061.87%

成交量：3,371.00

成交額：100.45

市值：641.26萬

市盈率：-0.15

高：0.0326

開：0.0300

低：0.0275

收：0.0320

52周最高：0.0800

52周最低：0.0253

股本：1.97億

流通股本：1.97億

量比：0.15

換手率：0.00%

股息：- -

股息率：- -

每股收益(TTM):-0.2138

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

Tevogen.AI 宣佈 Predictcell™ Beta 版取得新進展，精準度指標提升並擴展專有AI基礎設施

Tevogen Bio Holdings 評估收購 Sciometrix 及 Clinicus 平台以監測長期新冠症狀

Tevogen Bio Holdings Inc.盤中異動快速跳水5.01%

Tevogen推進仿製藥戰略，簽署意向書評估收購Apozeal製藥的潛在可能

Tevogen Bio Holdings Inc 正積極考慮其他交易，重點聚焦生命科學相關業務

Tevogen Bio Holdings簽署意向書擬評估收購Sciometrix及其數字護理管理平台Clinicus

Tevogen Bio Holdings Inc.盤中異動股價大漲6.06%報0.294美元

Tevogen Bio Holdings Inc.盤中異動早盤股價大跌5.20%報0.332美元

Tevogen Bio Holdings Inc.盤中異動快速上漲6.10%報0.411美元

Tevogen宣佈重大臨床里程碑：擴展其針對急性和長期新冠的精準T細胞治療的HLA覆蓋範圍

Tevogen Bio Holdings Inc.盤中異動下午盤急速跳水5.44%

Tevogen Bio Holdings Inc.盤中異動快速下挫5.39%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/TVGNW/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"TVGNW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGNW\",,,,,undefined,":{"symbol":"TVGNW","market":"US","secType":"STK","nameCN":"Tevogen Bio Holdings Inc.","latestPrice":0.0326,"timestamp":1774641600000,"preClose":0.032,"halted":0,"volume":3371,"delay":0,"changeRate":0.018749999999999885,"floatShares":196705066,"shares":196705066,"eps":-0.2138,"marketStatus":"休市中","change":0.0006,"latestTime":"03-27 16:00:00 EDT","open":0.03,"high":0.0326,"low":0.0275,"amount":100.4452,"amplitude":0.159375,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.2138,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.032,"volumeRatio":0.152658},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGNW\",,,,,undefined,":{"symbol":"TVGNW","floatShares":196705066,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.152658,"shares":196705066,"dividePrice":0,"high":0.0326,"amplitude":0.159375,"preClose":0.032,"low":0.0275,"week52Low":0.0253,"pbRate":"--","week52High":0.08,"institutionHeld":0,"latestPrice":0.0326,"eps":-0.2138,"divideRate":0,"volume":3371,"delay":0,"ttmEps":-0.2138,"open":0.03,"prevYearClose":0.0422,"prevWeekClose":0.036,"prevMonthClose":0.0448,"prevQuarterClose":0.0422,"fiveDayClose":0.036,"twentyDayClose":0.0448,"sixtyDayClose":0.0422},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVGNW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-02-15","symbol":"TVGNW","reason":null,"defaultRemindTime":1708007400000,"announcedDate":"2024-02-14","type":"delisting","dateTimestamp":1707973200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVGNW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVGNW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVGNW\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1165653461","title":"Tevogen.AI 宣佈 Predictcell™ Beta 版取得新進展，精準度指標提升並擴展專有AI基礎設施","url":"https://stock-news.laohu8.com/highlight/detail?id=1165653461","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165653461?lang=zh_tw&edition=fundamental","pubTime":"2026-03-14 00:31","pubTimestamp":1773419470,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings (TVGN) 近日披露了其人工智能平台 Predictcell™ Beta 版本的多项重要进展。该版本在精准度指标上展现出显著优化，同时公司还进一步扩展了其专有的AI基础设施架构。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","TVGNW","BK4139"],"gpt_icon":0},{"id":"1123137439","title":"Tevogen Bio Holdings 評估收購 Sciometrix 及 Clinicus 平台以監測長期新冠症狀","url":"https://stock-news.laohu8.com/highlight/detail?id=1123137439","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123137439?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 03:16","pubTimestamp":1773256571,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. 正在考虑收购 Sciometrix 和 Clinicus 平台，旨在加强对长期新冠（Long Covid）的监测能力。此举显示该公司正积极拓展其在生物科技领域的布局，特别是在应对新冠后遗症方面寻求新的解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","TVGNW","BK4139"],"gpt_icon":0},{"id":"2618118139","title":"Tevogen Bio Holdings Inc.盤中異動 快速跳水5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618118139","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618118139?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 21:41","pubTimestamp":1773236461,"startTime":"0","endTime":"0","summary":"北京时间2026年03月11日21时41分，Tevogen Bio Holdings Inc.股票出现波动，股价快速跳水5.01%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中，整体跌幅为0.35%。Tevogen Bio Holdings Inc.公司简介：Tevogen Bio Holdings Inc 是一家临床阶段的专科免疫治疗公司，利用CD8细胞毒性T淋巴细胞，开发现成的精准T细胞疗法用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311214101a6b84e82&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311214101a6b84e82&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TVGNW","TVGN","BK4139"],"gpt_icon":0},{"id":"1135990684","title":"Tevogen推進仿製藥戰略，簽署意向書評估收購Apozeal製藥的潛在可能","url":"https://stock-news.laohu8.com/highlight/detail?id=1135990684","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135990684?lang=zh_tw&edition=fundamental","pubTime":"2026-03-06 03:51","pubTimestamp":1772740289,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings（简称Tevogen）近日在仿制药业务布局上迈出关键一步，公司已签署意向书，正式启动对Apozeal制药的潜在收购评估。此举标志着Tevogen正加速拓展其仿制药产品线，以强化在生物医药领域的市场竞争力。通过本次战略评估，Tevogen有望进一步整合行业资源，提升其在全球仿制药市场的份额。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139","TVGNW"],"gpt_icon":0},{"id":"1146346246","title":"Tevogen Bio Holdings Inc 正積極考慮其他交易，重點聚焦生命科學相關業務","url":"https://stock-news.laohu8.com/highlight/detail?id=1146346246","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146346246?lang=zh_tw&edition=fundamental","pubTime":"2026-03-06 03:51","pubTimestamp":1772740274,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc 目前正积极评估其他交易机会，并将战略重点明确锁定在生命科学领域的相关业务上。公司此举旨在进一步拓展其在生物科技行业的影响力，并探索潜在的协同增长机会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","TVGNW","BK4139"],"gpt_icon":0},{"id":"1106152731","title":"Tevogen Bio Holdings簽署意向書 擬評估收購Sciometrix及其數字護理管理平台Clinicus","url":"https://stock-news.laohu8.com/highlight/detail?id=1106152731","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106152731?lang=zh_tw&edition=fundamental","pubTime":"2026-02-26 22:20","pubTimestamp":1772115616,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings已签署意向书，正就潜在收购医疗科技公司Sciometrix及其创新数字护理管理平台Clinicus展开评估。此次战略举措旨在整合Clinicus的智能化患者管理技术，强化Tevogen在精准医疗领域的数字化服务能力。\n该平台通过人工智能驱动的远程监测系统，可实现个性化治疗方案的动态优化。若交易顺利完成，将显著提升Tevogen在细胞疗法商业化过程中的患者全周期管理效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGNW","TVGN","BK4139"],"gpt_icon":0},{"id":"2612259751","title":"Tevogen Bio Holdings Inc.盤中異動 股價大漲6.06%報0.294美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612259751","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612259751?lang=zh_tw&edition=fundamental","pubTime":"2026-02-20 00:20","pubTimestamp":1771518007,"startTime":"0","endTime":"0","summary":"北京时间2026年02月20日00时20分，Tevogen Bio Holdings Inc.股票出现异动，股价大幅拉升6.06%。截至发稿，该股报0.294美元/股，成交量26.4044万股，换手率0.13%，振幅5.38%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中，整体跌幅为0.39%。Tevogen Bio Holdings Inc.公司简介：Tevogen Bio Holdings Inc 是一家临床阶段的专科免疫治疗公司，利用CD8细胞毒性T淋巴细胞，开发现成的精准T细胞疗法用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220002007a4b3d280&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220002007a4b3d280&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TVGNW","TVGN","BK4139"],"gpt_icon":0},{"id":"2606786226","title":"Tevogen Bio Holdings Inc.盤中異動 早盤股價大跌5.20%報0.332美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606786226","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606786226?lang=zh_tw&edition=fundamental","pubTime":"2026-01-26 23:58","pubTimestamp":1769443133,"startTime":"0","endTime":"0","summary":"北京时间2026年01月26日23时58分，Tevogen Bio Holdings Inc.股票出现异动，股价大幅跳水5.20%。截至发稿，该股报0.332美元/股，成交量7.9391万股，换手率0.04%，振幅4.77%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中，整体涨幅为0.49%。Tevogen Bio Holdings Inc.公司简介：Tevogen Bio Holdings Inc 是一家临床阶段的专科免疫治疗公司，利用CD8细胞毒性T淋巴细胞，开发现成的精准T细胞疗法用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126235853a6af01f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126235853a6af01f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TVGN","BK4139","TVGNW"],"gpt_icon":0},{"id":"2584941954","title":"Tevogen Bio Holdings Inc.盤中異動 快速上漲6.10%報0.411美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2584941954","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584941954?lang=zh_tw&edition=fundamental","pubTime":"2025-11-18 22:34","pubTimestamp":1763476478,"startTime":"0","endTime":"0","summary":"北京时间2025年11月18日22时34分，Tevogen Bio Holdings Inc.股票出现波动，股价急速上涨6.10%。截至发稿，该股报0.411美元/股，成交量5.7367万股，换手率0.03%，振幅3.95%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中，整体跌幅为0.20%。Tevogen Bio Holdings Inc.公司简介：Tevogen Bio Holdings Inc 是一家临床阶段的专科免疫治疗公司，利用CD8细胞毒性T淋巴细胞，开发现成的精准T细胞疗法用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118223438a70225ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118223438a70225ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TVGN","TVGNW","BK4139"],"gpt_icon":0},{"id":"1141099932","title":"Tevogen宣佈重大臨床里程碑：擴展其針對急性和長期新冠的精準T細胞治療的HLA覆蓋範圍","url":"https://stock-news.laohu8.com/highlight/detail?id=1141099932","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141099932?lang=zh_tw&edition=fundamental","pubTime":"2025-11-06 04:20","pubTimestamp":1762374032,"startTime":"0","endTime":"0","summary":"Tevogen宣布重大临床里程碑：扩展其针对急性和长期新冠的精准T细胞治疗的HLA覆盖范围","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGNW","TVGN"],"gpt_icon":0},{"id":"2581834794","title":"Tevogen Bio Holdings Inc.盤中異動 下午盤急速跳水5.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581834794","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581834794?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 03:09","pubTimestamp":1762283362,"startTime":"0","endTime":"0","summary":"北京时间2025年11月05日03时09分，Tevogen Bio Holdings Inc.股票出现波动，股价快速下跌5.44%。截至发稿，该股报0.556美元/股，成交量26.711万股，换手率0.14%，振幅5.71%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中，整体跌幅为0.03%。Tevogen Bio Holdings Inc.公司简介：Tevogen Bio Holdings Inc 是一家临床阶段的专科免疫治疗公司，利用CD8细胞毒性T淋巴细胞，开发现成的精准T细胞疗法用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110503092297540342&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110503092297540342&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TVGNW","TVGN"],"gpt_icon":0},{"id":"2572665597","title":"Tevogen Bio Holdings Inc.盤中異動 快速下挫5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2572665597","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572665597?lang=zh_tw&edition=fundamental","pubTime":"2025-10-03 22:08","pubTimestamp":1759500498,"startTime":"0","endTime":"0","summary":"北京时间2025年10月03日22时08分，Tevogen Bio Holdings Inc.股票出现异动，股价急速下跌5.39%。截至发稿，该股报0.737美元/股，成交量15.9692万股，换手率0.08%，振幅6.16%。Tevogen Bio Holdings Inc.股票所在的生物技术行业中，整体涨幅为0.05%。Tevogen Bio Holdings Inc.公司简介：Tevogen Bio Holdings Inc 是一家临床阶段的专科免疫治疗公司，利用CD8细胞毒性T淋巴细胞，开发现成的精准T细胞疗法用于治疗传染病、癌症和神经系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251003220818a4526c16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251003220818a4526c16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TVGN","BK4139","TVGNW"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}]}}